pentoxifylline has been researched along with Kidney Diseases in 30 studies
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "73 m(2) and proteinuria with protein greater than 500 mg/g of creatinine on treatment with losartan, 100 mg/d, for longer than 6 months were screened in National Taiwan University Hospital." | 9.13 | Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2008) |
| " Conclusion of this review is that short-term use of PTF may produce a significant reduction of proteinuria in subjects with diabetic and also non-diabetic kidney diseases but the reports of long-term use of PTF also show that urinary protein excretion exhibits a progressive and sustained reduction in patients treated with PTF." | 6.47 | A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria. ( Abdollahi, M; Badri, S; Dashti-Khavidaki, S; Lessan-Pezeshki, M, 2011) |
| "Proteinuria was diagnosed in 2003 (DPE 3." | 5.35 | [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline]. ( Larczyński, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Zietkiewicz, M, 2008) |
| "73 m(2) and proteinuria with protein greater than 500 mg/g of creatinine on treatment with losartan, 100 mg/d, for longer than 6 months were screened in National Taiwan University Hospital." | 5.13 | Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2008) |
| "Previous studies have reported that pentoxifylline, a phosphodiesterase inhibitor, attenuates experimental mesangial proliferative glomerulonephritis." | 3.71 | Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. ( Chen, YM; Chiang, WC; Chien, CT; Lin, SL; Tsai, CC; Tsai, TJ, 2002) |
| "Pentoxifylline was not significantly associated with increase or decrease in the risk of CIN (RR 0." | 2.82 | The role of pentoxifylline in preventing contrast-induced nephropathy in coronary angiography/intervention - systematic review, meta-analysis, and meta-regression of randomized controlled trials. ( Akbar, MR; Martha, JW; Pranata, R; Raffaello, WM; Wibowo, A, 2022) |
| "Treatment with pentoxifylline reduced circulating IL-6 (6." | 2.75 | Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. ( Ferrari, P; Mallon, D; Olynyk, JK; Trinder, D, 2010) |
| "For pentoxifylline-treated participants, the mean estimated GFR decrease during treatment was slower compared with the year before study enrollment (-9." | 2.74 | Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. ( Aboudara, MC; Cushner, HM; Olson, SW; Perkins, RM; Uy, AL; Yuan, CM, 2009) |
| " Conclusion of this review is that short-term use of PTF may produce a significant reduction of proteinuria in subjects with diabetic and also non-diabetic kidney diseases but the reports of long-term use of PTF also show that urinary protein excretion exhibits a progressive and sustained reduction in patients treated with PTF." | 2.47 | A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria. ( Abdollahi, M; Badri, S; Dashti-Khavidaki, S; Lessan-Pezeshki, M, 2011) |
| "Pentoxifylline (PTX) is an anti-inflmmatory and anti-oxidant agent." | 1.37 | Protective effect of pentoxyfilline in renal toxicity after methotrexate administration. ( Asl, NA; Asvadi, A; Asvadi, I; Hajipour, B; Khodadadi, A; Roshangar, L, 2011) |
| "Proteinuria was diagnosed in 2003 (DPE 3." | 1.35 | [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline]. ( Larczyński, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Zietkiewicz, M, 2008) |
| "Pentoxifylline (PTX) has been shown to inhibit cytokine synthesis, including TNF-alpha." | 1.35 | Pentoxifylline prevents the meglumine antimonate-induced renal toxicity in rats, but not that induced by the inorganic antimony pentachloride. ( de Moura, FJ; de Souza Furtado, R; Leal, PP; Muniz-Junqueira, MI; Veiga, JP, 2008) |
| "Glycerol treated rats exhibited collecting duct and medullary ascending limb dilation and casts, with focal tubular damage, confined mainly to the superficial cortex." | 1.31 | Nephroprotective effects of pentoxifylline in experimental myoglobinuric acute renal failure. ( Avramovic, V; Djordjevic, V; Mitic-Zlatkovic, M; Savic, V; Stefanovic, V; Vlahovic, P, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (26.67) | 18.2507 |
| 2000's | 10 (33.33) | 29.6817 |
| 2010's | 9 (30.00) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martha, JW | 1 |
| Pranata, R | 1 |
| Raffaello, WM | 1 |
| Wibowo, A | 1 |
| Akbar, MR | 1 |
| El Magdoub, HM | 1 |
| Schaalan, MF | 1 |
| Rahmo, RM | 1 |
| Farag, DB | 1 |
| Khedr, LH | 1 |
| Wei, L | 1 |
| Zhang, W | 1 |
| Yang, Y | 1 |
| Li, D | 1 |
| Kasap, B | 1 |
| Türkmen, M | 1 |
| Kiray, M | 1 |
| Kuralay, F | 1 |
| Soylu, A | 1 |
| Tuğyan, K | 1 |
| Kavukçu, S | 1 |
| Kao, CC | 1 |
| Wu, MS | 1 |
| Armagan, I | 1 |
| Bayram, D | 2 |
| Candan, IA | 1 |
| Yigit, A | 1 |
| Celik, E | 1 |
| Armagan, HH | 1 |
| Uğuz, AC | 1 |
| Farag, MM | 1 |
| Khalifa, AA | 1 |
| Elhadidy, WF | 1 |
| Rashad, RM | 1 |
| Lin, SL | 2 |
| Chen, YM | 2 |
| Chiang, WC | 2 |
| Wu, KD | 1 |
| Tsai, TJ | 2 |
| Renke, M | 2 |
| Rutkowski, P | 2 |
| Tylicki, L | 2 |
| Zietkiewicz, M | 2 |
| Larczyński, W | 2 |
| Rutkowski, B | 2 |
| Ozer, MK | 1 |
| Asci, H | 1 |
| Oncu, M | 1 |
| Yesilot, S | 1 |
| Savran, M | 1 |
| Cicek, E | 1 |
| Perkins, RM | 1 |
| Aboudara, MC | 1 |
| Uy, AL | 1 |
| Olson, SW | 1 |
| Cushner, HM | 1 |
| Yuan, CM | 1 |
| Stojiljković, N | 1 |
| Veljković, S | 1 |
| Mihailović, D | 1 |
| Stoiljković, M | 1 |
| Ranković, G | 1 |
| Jovanović, I | 1 |
| Randjelović, P | 1 |
| Ferrari, P | 1 |
| Mallon, D | 1 |
| Trinder, D | 1 |
| Olynyk, JK | 1 |
| Shah, SV | 1 |
| Ozkurkcugil, C | 1 |
| Yilmaz, MY | 1 |
| Ozkan, L | 1 |
| Kokturk, S | 1 |
| Isken, T | 1 |
| Badri, S | 1 |
| Dashti-Khavidaki, S | 1 |
| Lessan-Pezeshki, M | 1 |
| Abdollahi, M | 1 |
| Asvadi, I | 1 |
| Hajipour, B | 1 |
| Asvadi, A | 1 |
| Asl, NA | 1 |
| Roshangar, L | 1 |
| Khodadadi, A | 1 |
| Chien, CT | 1 |
| Tsai, CC | 1 |
| Savic, V | 1 |
| Vlahovic, P | 1 |
| Djordjevic, V | 1 |
| Mitic-Zlatkovic, M | 1 |
| Avramovic, V | 1 |
| Stefanovic, V | 1 |
| Usta, Y | 1 |
| Ismailoglu, UB | 1 |
| Bakkaloglu, A | 1 |
| Orhan, D | 1 |
| Besbas, N | 1 |
| Sahin-Erdemli, I | 1 |
| Ozen, S | 1 |
| de Moura, FJ | 1 |
| Leal, PP | 1 |
| de Souza Furtado, R | 1 |
| Muniz-Junqueira, MI | 1 |
| Veiga, JP | 1 |
| Stockschläder, M | 1 |
| Kalhs, P | 1 |
| Peters, S | 1 |
| Zeller, W | 1 |
| Krüger, W | 1 |
| Kabisch, H | 1 |
| Lechner, K | 1 |
| Zander, A | 1 |
| Ates, E | 1 |
| Sharma, P | 1 |
| Erkasap, S | 1 |
| Talbot, D | 1 |
| Ihtiyar, E | 1 |
| Yasar, B | 1 |
| Kiper, H | 1 |
| Vadiei, K | 2 |
| Tucker, SD | 1 |
| Lopez-Berestein, G | 2 |
| Wasan, KM | 2 |
| Frantz, RP | 1 |
| Edwards, BS | 1 |
| Olson, LJ | 1 |
| Schwab, MK | 1 |
| Adams, TF | 1 |
| Textor, SC | 1 |
| Daly, RC | 1 |
| McGregor, CG | 1 |
| Rodeheffer, RJ | 1 |
| Albornoz, LE | 1 |
| Sanchez, SB | 1 |
| Bandi, JC | 1 |
| Canteros, G | 1 |
| de las Heras, M | 1 |
| Mastai, RC | 1 |
| Bennett, WM | 1 |
| Elzinga, LW | 1 |
| Porter, GA | 1 |
| Rosen, S | 1 |
| Bianco, JA | 1 |
| Almgren, J | 1 |
| Kern, DL | 1 |
| Ballard, B | 1 |
| Roark, K | 1 |
| Andrews, F | 1 |
| Nemunaitis, J | 1 |
| Shields, T | 1 |
| Singer, JW | 1 |
| Verani, RR | 1 |
| Luke, DR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients: a Pilot Randomized, Placebo-controlled, Double-blind Trial.[NCT00285298] | Phase 3 | 39 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Impact of Pentoxifylline Administration on the Modulation of Hyporesponsiveness to Erythropoietin Stimulating Agents in Hemodialysis Patients[NCT03800433] | Early Phase 1 | 46 participants (Anticipated) | Interventional | 2019-10-31 | Not yet recruiting | ||
| Is Hepcidin a Possible Contributor to Impaired Iron Mobilization and Anaemia in Hepatitis C Patients Treated With Pegylated Interferon Alpha and Ribavirin Therapy? A Pilot Study[NCT01726400] | 15 participants (Actual) | Observational | 2012-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for pentoxifylline and Kidney Diseases
| Article | Year |
|---|---|
The role of pentoxifylline in preventing contrast-induced nephropathy in coronary angiography/intervention - systematic review, meta-analysis, and meta-regression of randomized controlled trials.
Topics: Contrast Media; Coronary Angiography; Creatinine; Humans; Kidney Diseases; Male; Pentoxifylline; Ran | 2022 |
Pentoxifylline for the prevention of contrast-induced nephropathy: systematic review and meta-analysis of randomised controlled trials.
Topics: Contrast Media; Coronary Angiography; Creatinine; Humans; Kidney Diseases; Pentoxifylline; Randomize | 2021 |
[Pentoxifylline old drug or new hope for nephrology?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Cytokines; Humans; Kidney Diseases; Pento | 2008 |
Progress toward novel treatments for chronic kidney disease.
Topics: Amides; Anticoagulants; Antihypertensive Agents; Bicarbonates; Chronic Disease; Enzyme Inhibitors; F | 2010 |
A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria.
Topics: Animals; Chronic Disease; Diabetic Nephropathies; Disease Progression; Humans; Kidney Diseases; Kidn | 2011 |
4 trials available for pentoxifylline and Kidney Diseases
| Article | Year |
|---|---|
Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Chemokine CCL2; | 2008 |
Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Chronic Dis | 2009 |
Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease.
Topics: Anemia, Iron-Deficiency; Biomarkers; Chronic Disease; Ferritins; Hematinics; Hemoglobins; Humans; In | 2010 |
Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease.
Topics: Anemia, Iron-Deficiency; Biomarkers; Chronic Disease; Ferritins; Hematinics; Hemoglobins; Humans; In | 2010 |
Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease.
Topics: Anemia, Iron-Deficiency; Biomarkers; Chronic Disease; Ferritins; Hematinics; Hemoglobins; Humans; In | 2010 |
Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease.
Topics: Anemia, Iron-Deficiency; Biomarkers; Chronic Disease; Ferritins; Hematinics; Hemoglobins; Humans; In | 2010 |
Effects of pentoxifylline on renal function and blood pressure in cardiac transplant recipients: a randomized trial.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Weight; Cyclosporine; Doubl | 1997 |
21 other studies available for pentoxifylline and Kidney Diseases
| Article | Year |
|---|---|
Implications of miRNAs on TGF-β/TAK1/mTOR pathway in mediating the renoprotective effects of pentoxifylline against cisplatin-induced nephrotoxicity in rats.
Topics: Animals; Binding Sites; Cisplatin; Gene Expression Regulation; Kidney Diseases; Male; MAP Kinase Kin | 2020 |
Effects of pentoxifylline on gentamicin-induced nephrotoxicity.
Topics: Animals; Anti-Bacterial Agents; Drug Evaluation, Preclinical; Female; Free Radical Scavengers; Genta | 2013 |
Renoprotective effect of pentoxifylline in advanced chronic kidney disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropathies; | 2015 |
Effects of pentoxifylline and alpha lipoic acid on methotrexate-induced damage in liver and kidney of rats.
Topics: Animals; Antioxidants; Biomarkers; Chemical and Drug Induced Liver Injury; Disease Models, Animal; G | 2015 |
Hepatorenal protection in renal ischemia/reperfusion by celecoxib and pentoxifylline.
Topics: Animals; Biomarkers; Celecoxib; Drug Administration Schedule; Drug Therapy, Combination; Kidney; Kid | 2016 |
[Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type | 2008 |
Effects of pentoxifylline on amikacin-induced nephrotoxicity in rats.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Blood Urea Nitrogen; Creatinine; Free Radical Scavengers; | 2009 |
Pentoxifylline ameliorates glomerular basement membrane ultrastructural changes caused by gentamicin administration in rats.
Topics: Animals; Anti-Bacterial Agents; Apoptosis; Basement Membrane; Gentamicins; Kidney Diseases; Kidney G | 2009 |
Protective effects of pentoxifylline on cigarette smoking-induced renal tissue damage in rats.
Topics: Animals; Apoptosis; Disease Models, Animal; In Situ Nick-End Labeling; Kidney; Kidney Diseases; Kidn | 2011 |
Protective effect of pentoxyfilline in renal toxicity after methotrexate administration.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Biomarkers; Blood Urea Nitrogen; Creatin | 2011 |
Pentoxifylline attenuated the renal disease progression in rats with remnant kidney.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cell Division; Cells, Cultured; C | 2002 |
Nephroprotective effects of pentoxifylline in experimental myoglobinuric acute renal failure.
Topics: Acute Kidney Injury; Animals; Glomerular Mesangium; Glycerol; Kidney; Kidney Diseases; Kidney Glomer | 2002 |
Effects of pentoxifylline in adriamycin-induced renal disease in rats.
Topics: Animals; Apoptosis; Doxorubicin; Kidney Diseases; Pentoxifylline; Proteinuria; Rats; Rats, Wistar; T | 2004 |
Pentoxifylline prevents the meglumine antimonate-induced renal toxicity in rats, but not that induced by the inorganic antimony pentachloride.
Topics: Animals; Antimony; Antiprotozoal Agents; Chlorides; Dose-Response Relationship, Drug; Kidney Disease | 2008 |
Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients.
Topics: Adolescent; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Child; Cyclophosphami | 1993 |
Cyclosporine nephrotoxicity in the ischemic kidney and the protective effect of pentoxifylline--a study in the rat.
Topics: Animals; Calcinosis; Creatinine; Cyclosporine; Ischemia; Kidney; Kidney Diseases; Kidney Tubules; Li | 1996 |
Nephroprotective mechanism(s) of pentoxifylline: reduction of erythrocyte-mediated vascular congestion and inhibition of nitric oxide release.
Topics: Animals; Erythrocytes; Ischemia; Kidney; Kidney Diseases; Male; Nitric Oxide; Pentoxifylline; Periph | 1996 |
Pentoxifylline reduces nephrotoxicity associated with cyclosporine in the rat by its rheological properties.
Topics: Animals; Arteries; Blood Pressure; Blood Viscosity; Cyclosporine; Hemodynamics; Kidney; Kidney Disea | 1997 |
The effects of pentoxifylline on experimental chronic cyclosporine nephrotoxicity.
Topics: Animals; Cyclosporine; Fibrosis; Kidney; Kidney Diseases; Male; Pentoxifylline; Rats; Rats, Sprague- | 1992 |
Evidence that oral pentoxifylline reverses acute renal dysfunction in bone marrow transplant recipients receiving amphotericin B and cyclosporine. Results of a pilot study.
Topics: Administration, Oral; Adult; Amphotericin B; Bone Marrow Transplantation; Cyclosporins; Humans; Kidn | 1991 |
Pentoxifylline in amphotericin B toxicity rat model.
Topics: Amphotericin B; Animals; Kidney; Kidney Diseases; Male; Pentoxifylline; Rats; Renal Circulation; The | 1990 |